<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1553">
  <stage>Registered</stage>
  <submitdate>3/11/1994</submitdate>
  <approvaldate>3/11/1994</approvaldate>
  <actrnumber>ACTRN12607000029493</actrnumber>
  <trial_identification>
    <studytitle>IBCSG IX - Adjuvant therapy in postmenopausal patients with node negative breast cancer</studytitle>
    <scientifictitle>Adjuvant therapy in postmenopausal patients with node negative breast cancer</scientifictitle>
    <utrn />
    <trialacronym>IBCSG IX</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR92</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm B: CMF (cyclophosphamide 100mg /m^2 orally days 1-14, Methotrexate i.v. 40mg/m^2 days 1 and 8 and 5-Fluorouracil i.v. 600mg/m^2 days 1 and 8) for three cycles (cycle duration is 28 days) followed by Tamoxifen (20mg orally daily for 57months  addendum 3). Combined this gives a total duration of treatment of 60 months.</interventions>
    <comparator>Arm A: Tamoxifen (20mg orally daily for 60 months  addendum 3)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease-free survival (DFS) where all relapses, second primary tumours and deaths without recurrence are counted as failures.</outcome>
      <timepoint>Patients are assessed for disease status every 3 months during the first year on study, every 6 months during year 2 and annually thereafter for life.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Patients are assessed for survival, treatment-related side effects and systemic recurrence at each chemotherapy cycle administration, every 3 months during the first year on study, every 6 months during year 2 and annually thereafter for life.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patterns of relapse</outcome>
      <timepoint>Patterns of relapse will be reviewed by the Data Safety and Monitoring Committee at semi-annual meetings.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related side effects</outcome>
      <timepoint>Patients are assessed for survival, treatment-related side effects and systemic recurrence at each chemotherapy cycle administration, every 3 months during the first year on study, every 6 months during year 2 and annually thereafter for life.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Systemic disease-free survival</outcome>
      <timepoint>Will be monitored for the duration of the trial for possible early termination of patient entry.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life</outcome>
      <timepoint>Quality of Life is assessed every 3 months during the first year on study, every 6 months during year 2 and annually until year 6.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Postmenopausal women who are:a) &gt; 52 years, with at least 1 year amenorrhea; orb) &lt; or equal to 52 years with 3 or more years of amenorrhea; or c) &gt; 55 years and have had hysterectomy without bilateral oophorectomy; ord) Biochemical evidence of cessation of ovarian function (in questionable cases)Patients must have had:a. Either total mastectomy, or breast conserving procedure (lumpectomy or quadrantectomy)b. Axillary clearance with at least 8 lymph nodes for pathological examinationc. Surgical procedure within 6 weeks prior to randomisation Node negative disease (without metastases detected at pathologic examination in at least 8 ipsilateral axillary nodes) Eight lymph nodes histopathologically examined Tumour confined to breast with no detected metastases Adequate marrow function (WBC &gt; 400/mm3 and platelets &gt; 100,000/mm3 Documented evidence of adequate renal (creatinine &lt; 120umol/l) and hepatic (bilirubin &lt; 20umol/l, SGOT &lt; 60 IU/l) function Informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Axillary node involvement Malignant breast tumours other than carcinoma T4 tumours with ulceration or infiltration of skin, peau d' orange, or metastatic disease Bilateral malignancies, or mass in opposite breast, unless mass is proven by biopsy to be non-malignant Less than total mastectomy procedure in which margins of resection contained tumour cells, after which they did not subsequently undergo total mastectomy Premenopausal patients Previous or concurrent malignancy, except patients with squamous or basal cell carcinoma of skin, or in-situ carcinoma of cervix Prior therapy for breast cancer, including irradiation, surgery, or chemo- and/or hormonal therapy Other non-malignant systemic diseases preventing treatment options or prolonged follow-up Psychiatric or addictive disorders preventing informed consent or treatment options Bone scan showing hot spots which cannot be confirmed as benign disease, or skeletal pain of unknown cause Estrogen receptor negative tumours or are oestrogen receptor status unknown (addendum 12).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone</concealment>
    <sequence>Computer generated stratified blocks</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/10/1988</anticipatedstartdate>
    <actualstartdate>3/04/1989</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/08/1999</actualenddate>
    <samplesize>900</samplesize>
    <actualsamplesize>1715</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>International Breast Cancer Study Group</primarysponsorname>
    <primarysponsoraddress>Effingerstrasse 40, 3008 Bern</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Australia and New Zealand Breast Cancer Trials Group</fundingname>
      <fundingaddress>PO BOX 155
HRMC NSW 2310</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australia and New Zealand Breast Cancer Trials Group</sponsorname>
      <sponsoraddress>PO BOX 155
HRMC NSW 2310</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomised clinical trial will compare the combination of three cycles of chemotherapy (CMF) followed by tamoxifen versus tamoxifen alone in postmenopausal patients with node negative, oestrogen receptor positive breast cancer to determine which therapeutic strategy is better in terms of disease-free survival, overall survival and quality of life.</summary>
    <trialwebsite />
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Dubbo Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/10/1988</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney Adventist Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bendigo Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital, Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mount Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Waikato Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+ 61 2 4985 0113</phone>
      <fax>+ 61 2 4960 1539</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax>+61 2 4985 0141</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax />
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>